Minimizing the immunogenicity of protein therapeutics

被引：137

作者：

Chirino, AJ ^{[1
]}

Ary, ML ^{[1
]}

Marshall, SA ^{[1
]}

机构：

[1] Xencor, Monrovia, CA 91016 USA

来源：

DRUG DISCOVERY TODAY | 2004年 / 9卷 / 02期

关键词：

D O I：

10.1016/S1359-6446(03)02953-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

As is cautioned in many package inserts, 'with all therapeutic proteins, there is a potential for immunogenicity'. Immunogenicity problems in humans, which currently can be detected only in clinical trials or after product launch, pose a significant barrier to the development and acceptance of protein drugs. Recent and ongoing research, presented in this review, seeks to address the challenge of protein therapeutic immunogenicity by elucidating the mechanisms underlying immune recognition of protein therapeutics, establishing preclinical methods for assessing immunogenicity and developing strategies for minimizing immune responses.

引用

收藏

页码：82 / 90

页数：9

相关论文

共 64 条

[1] T-cell epitope mapping using the ELISPOT approach [J].

Anthony, DD ;

Lehmann, PV .

METHODS, 2003, 29 (03) :260-269

[2]

Antonelli G, 1997, J INTERF CYTOK RES, V17, pS39

[3] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[4] Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].

Bailon, P ;

Palleroni, A ;

Schaffer, CA ;

Spence, CL ;

Fung, WJ ;

Porter, JE ;

Ehrlich, GK ;

Pan, W ;

Xu, ZX ;

Modi, MW ;

Farid, A ;

Berthold, W .

BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202

[5]

BARBOSA MDF, 2003, 90 M AM SOC IMM 6 10

[6] Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules [J].

Barrow, RT ;

Healey, JF ;

Gailani, D ;

Scandella, D ;

Lollar, P .

BLOOD, 2000, 95 (02) :564-568

[7] Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice [J].

Braun, A ;

Kwee, L ;

Labow, MA ;

Alsenz, J .

PHARMACEUTICAL RESEARCH, 1997, 14 (10) :1472-1478

[8] DETECTION OF PEPTIDE-MHC CLASS-II COMPLEXES ON THE SURFACE OF INTACT-CELLS [J].

BUSCH, R ;

ROTHBARD, JB .

JOURNAL OF IMMUNOLOGICAL METHODS, 1990, 134 (01) :1-22

[9] Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen [J].

Caillat-Zucman, S ;

Gimenez, JJ ;

Wambergue, F ;

Albouze, G ;

Lebkiri, B ;

Naret, C ;

Moynot, A ;

Jungers, P ;

Bach, JF .

KIDNEY INTERNATIONAL, 1998, 53 (06) :1626-1630

[10] Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].

Casadevall, N ;

Nataf, J ;

Viron, B ;

Kolta, A ;

Kiladjian, J ;

Martin-Dupont, P ;

Michaud, P ;

Papo, T ;

Ugo, V ;

Teyssandier, I ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475

← 1 2 3 4 5 6 7 →